Karen,
I haven't yet found abnormalities in the myeloid and erythroid
series in combination with increased megakaryocytes in non-MDS patients. My
non-MDS data base is post chemo-lymphoma patients (with no evidence of
MDS), some wierd "What do they have patients?", LGL patients and immune
deficiency patients (non-AIDS). We are constantly looking for these
patterns we have seen in non-MDS patients. Time will tell if we find some
who have them but so far, I feel multi lineage abnormalities are most
consistent with MDS.
Maryalice
>Maryalice--
>
>When you say these patterns are characteristic of MDS, does that mean that you
>and others have studied numbers of patients without MDS to look for these
>abnormalities. E.g. Patients with autoimmune disorders, immunodeficiencies (not
>just AIDS), toxic injury... I have seen several cases where patients were
>suggested to have MDS by flow studies performed by someone I would consider to
>be an expert in the field. In one of these patients the abnormalities
>spontaneously disappeared (they were restudied by the same lab a few months
>later). In the other case the young woman (I think in her 20's) appeared
>to have
>some sort of ill-defined autoimmune disorder. (This woman was being evaluated
>for bone marrow transplant because of her "MDS").
>
>I mention this only to emphasize your point that these findings need to be
>taken
>in context of the morphologic, cytogenetic and clinical findings.
>
>Happy Holidays.
>
>Karen
>
>
>Karen P. Mann, M.D., Ph.D.
>Duke University Medical Center
>Durham, NC
>
>_______________________________________________________________________________
>Subject: Re: hypocellular MDS
>From: stetler@box-s.nih.gov at internet
>Date: 12/26/97 12:10 PM
>
>Dear Patti,
> There is a great deal of research on going inthis area. I feel that
>if you can demonstrate distinct myeloid as well as erythroid abnormalities,
>then you have excellent support for a diagnosis of MDS. I know several
>distinguished flowers who have identified abnormal patterns they find
>characteristic of MDS.We have studies this topic ourselves and found
>myeloid and erythroid abnormalities in MDS. Our ability to detect these
>abnormalities is hampered by the quality of the specimen received. When we
>get 6 mL of bone marrow aspirate we get 3 mL of real bone marrow and 3mL of
>blood, if we are lucky. Luckily, the granulocytes are abnormal in MDS too.
>However, we get few erythroid precursors with a poor specimen. However,
>there are useful abnormal immunophenotypic findings in MDS.
> You ask if there is "" marker for MDS. I don't think there is a
>single marker for MDS, just as there isn't a single marker for follicular
>lymphoma, mantle cell lymphoma, AML or ALL. The idea of identifying any
>single immunophenotypic marker for diagnosis of a hematopoietic disorder is
>not a viable one. It is identification an abnormal pattern that can lead to
>the diagnosis. However, remember the consensus conference recommendations
>for flow of leukemias and lymphomas. I think they should apply to MD too.
>There needs always to be morphological correlation. If you would like more
>information please contact me or attend the clinical flow cytometry meeting
>in Charleston in August. There you can learn what is happening in this
>field.
>
> Maryalice
>
>
>>Dear flowers,
>>Are there any markers that will differentiate between hypocellular MDS
>>(refractory
>>anemia) from aplastic anemia?
>>Patcharin Tanawattanacharoen, MD
>>Hematology Branch
>>National Heart Lung and Blood Institute
>>National Institutes of Health
>>Bld 10 Room 7C112
>>9000 Rockville, MD 20892,USA
>>tel (301) 402 3477
>>fax (301) 496 8396
>>e-mail:tanawatp@gwgate.nhlbi.nih.gov
>
>Maryalice Stetler-Stevenson
>Director Flow Cytometry Unit
>Laboratory of Pathology, NCI, NIH
>
>
>
>RFC-822-headers:
>Received: from flowcyt.cyto.purdue.edu by mc.duke.edu (PMDF V5.1-10 #23776)
> with SMTP id <0ELT0026WNAN6H@mc.duke.edu>; Fri,
> 26 Dec 1997 19:14:39 -0500 (EST)
>Received: by flowcyt.cyto.purdue.edu (940816.SGI.8.6.9/930416.SGI.AUTO)
> for cyto-sendout id RAA06447; Fri, 26 Dec 1997 17:37:29 -0500
>Received: from courageous.dcrt.nih.gov by flowcyt.cyto.purdue.edu via ESMTP
> (940816.SGI.8.6.9/930416.SGI.AUTO) for <cytometry@flowcyt.cyto.purdue.edu> id
> MAA05846; Fri, 26 Dec 1997 12:06:29 -0500
>Received: from [128.231.220.102] ([128.231.220.102]) by courageous.dcrt.nih.gov
> (8.8.5/8.8.5) with SMTP id MAA27028; Fri, 26 Dec 1997 12:06:47 -0500 (EST)
>Date: Fri, 26 Dec 1997 13:10:53 -0400
>From: stetler@box-s.nih.gov (Maryalice Stetler-Stevenson)
>Subject: Re: hypocellular MDS
>X-Sender: stetler@POserver-s.nih.gov
>To: Cytometry Mailing List <cytometry@flowcyt.cyto.purdue.edu>
>Message-id: <b0c992b4050210045c2e@[128.231.220.102]>
>MIME-version: 1.0
>Content-type: text/plain; charset="us-ascii"
Maryalice Stetler-Stevenson
Director Flow Cytometry Unit
Laboratory of Pathology, NCI, NIH
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:51:38 EST